This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Bial's BIA 28-6156 fails Parkinson's trial
Business drug trial failure

Bial's BIA 28-6156 fails Parkinson's trial

Analysis based on 6 articles · First reported May 26, 2026 · Last updated Jun 09, 2026

Sentiment
-60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The failure of Bial's Pariceract in its Phase 2b ACTIVATE study for GBA1-associated Parkinson s disease is a negative development for the pharmaceutical industry, particularly for companies focused on neurosciences and rare diseases. This outcome could lead to increased investor caution regarding early-stage drug development in this challenging therapeutic area. For Bial, this represents a significant financial and reputational setback, potentially impacting its future R&D investments and stock valuation if it were publicly traded.

Pharmaceuticals Biotechnology
Event Summary

Bial, a biopharmaceutical company, announced the completion of its Phase 2b ACTIVATE study for Pariceract, a drug intended to treat GBA1-associated Parkinson s disease. Despite initial hopes, the study revealed that Pariceract failed to meet its primary and key secondary efficacy endpoints, meaning it did not significantly slow the progression of the disease compared to a placebo. Although the drug was generally well-tolerated with no unexpected safety concerns, Bial has decided to discontinue further development of Pariceract for this indication due to the lack of demonstrated efficacy. This outcome is a disappointment for the Parkinson s disease community, as it leaves a major unmet medical need unaddressed. Bial's CEO, António Portela, and CSO, Jörg Holenz, expressed gratitude to participants and emphasized the valuable scientific insights gained, which will inform future research efforts.

Entities Involved
priv
Bial
Bial announced the completion of its Phase 2b ACTIVATE study for Pariceract, which subsequently failed to meet its primary and key secondary efficacy endpoints, leading to the discontinuation of the drug's development for GBA1-associated Parkinson s disease. This represents a significant setback for Bial's R&D efforts in neurosciences.
Importance 100.0 Sentiment -70.0
oth
Pariceract
Pariceract, a drug in development by Bial for GBA1-associated Parkinson s disease, failed to meet its primary and key secondary efficacy endpoints in the Phase 2b ACTIVATE study, leading to its discontinuation. This marks the end of its development for this indication.
Importance 90.0 Sentiment -100.0
per
António Portela
As Chief Executive Officer of Bial, António Portela expressed disappointment with the study's outcome and affirmed Bial's continued commitment to finding treatments for Parkinson s disease.
Importance 60.0 Sentiment -50.0
per
Jörg Holenz
As Chief Scientific Officer of Bial, Jörg Holenz acknowledged the valuable insights gained from the ACTIVATE study despite the negative results, emphasizing their use to inform future therapeutic solutions.
Importance 60.0 Sentiment -50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.